Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

PubWeight™: 4.68‹?› | Rank: Top 1%

🔗 View Article (PMID 28121498)

Published in N Engl J Med on February 07, 2017


Mark H Wilcox1, Dale N Gerding1, Ian R Poxton1, Ciaran Kelly1, Richard Nathan1, Thomas Birch1, Oliver A Cornely1, Galia Rahav1, Emilio Bouza1, Christine Lee1, Grant Jenkin1, Werner Jensen1, You-Sun Kim1, Junichi Yoshida1, Lori Gabryelski1, Alison Pedley1, Karen Eves1, Robert Tipping1, Dalya Guris1, Nicholas Kartsonis1, Mary-Beth Dorr1, MODIFY I and MODIFY II Investigators

Author Affiliations

1: From Leeds Teaching Hospitals and University of Leeds, Leeds (M.H.W.), and the University of Edinburgh, Edinburgh (I.R.P.) - both in the United Kingdom; Loyola University Chicago Stritch School of Medicine, Maywood, and Edward Hines Jr. VA Hospital, Hines - both in Illinois (D.N.G.); Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (C.K.); Idaho Falls Infectious Disease, Idaho Falls, Idaho (R.N.); Holy Name Medical Center, Teaneck (T.B.), and Merck, Kenilworth (L.G., A.P., K.E., R.T., D.G., N.K., M.-B.D.) - both in New Jersey; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Department I of Internal Medicine, Clinical Trials Center Cologne (ZKS Köln), German Center for Infection Research (DZIF), University Hospital of Cologne, Cologne, Germany (O.A.C.); Sheba Medical Center, Tel Hashomer, Israel (G.R.); Hospital Gregorio Maranon, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES) (CB06/06/0058), Madrid (E.B.); St. Joseph's Healthcare, Hamilton, ON, Canada (C.L.); Monash Health, Clayton, VIC, Australia (G.J.); Gustavo Fricke Hospital, Viña del Mar, Chile (W.J.); Inje University Seoul Paik Hospital, Seoul, South Korea (Y.-S.K.); and Shimonoseki City Hospital, Shimonoseki, Japan (J.Y.).

Associated clinical trials:

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I) | NCT01241552

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (MODIFY II) | NCT01513239